SCHEMBL2678377

SCHEMBL2678377

O=C(O)CCCCSc1ccccn1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.79
KMT2A Q03164 3/20 0.63
MAPT P10636 2/20 0.63
HPGD P15428 3/20 0.53
SMN1; SMN2 Q16637 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
POLB P06746 1/20 0.50
MEN1 O00255 1/20 0.48
PKM P14618 1/20 0.48
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
LMNA P02545 1/20 0.47
RXFP1 Q9HBX9 1/20 0.46
PTGS2 P35354 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8916154 0.98 ALDH1A1 (0.77) ALDH1A1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL16564081 0.95 ALDH1A1 (0.81) ALDH1A1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL30602595 0.88 ALDH1A1 (1.00) ALDH1A1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL433102 0.88 ALDH1A1 (1.00) ALDH1A1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL3101921 0.84 ALDH1A1 (0.60) ALDH1A1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL17256326 0.83 ALDH1A1 (0.59) ALDH1A1KMT2AMAPTSMN1; SMN2RXFP1
SCHEMBL16387329 0.83 ALDH1A1 (0.59) ALDH1A1KMT2AMAPTSMN1; SMN2RXFP1
SCHEMBL14921878 0.83 ALDH1A1 (0.59) ALDH1A1KMT2AMAPTSMN1; SMN2RXFP1
SCHEMBL31005435 0.83 ALDH1A1 (0.59) ALDH1A1KMT2AMAPTSMN1; SMN2RXFP1
SCHEMBL7153037 0.82 HPGD (0.70) ALDH1A1KMT2AMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3013861-A1 ANTI-FCRH5 ANTIBODIES Genentech, Inc. (US) 2016-05-04 EP disclosed
EP-2962697-A1 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE diaDexus, Inc. (US) 2016-01-06 EP disclosed
EP-2104513-B1 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS INC (US) 2015-05-20 EP disclosed
WO-2014210064-A1 ANTI-FCRH5 ANTIBODIES GENENTECH, INC. (US) 2014-12-31 WO disclosed
US-20130224776-A1 PCan065 Antibody Compositions and Methods of Use DIADEXUS, INC. (US) 2013-08-29 US disclosed
US-20130022539-A1 OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS, INC. (US) 2013-01-24 US disclosed
US-20120329079-A1 Pro108 Antibody Compositions and Methods of Use and Use of Pro108 to Assess Cancer Risk DIADEXUS, INC. (US) 2012-12-27 US disclosed
EP-1817055-B1 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS INC (US) 2012-12-26 EP disclosed
US-20120263647-A1 Pro104 Antibody Compositions and Methods of Use DIADEXUS, INC. (US) 2012-10-18 US disclosed
US-8173434-B2 PCan065 antibody compositions and methods of use DIADEXUS, INC. (US) 2012-05-08 US disclosed
EP-1646357-A2 PRO104 ANTIBODY COMPOSITIONS AND METHODS OF USE Diadexus, Inc. (US) 2006-04-19 EP disclosed
EP-1633850-A2 Ovr115 ANTIBODY COMPOSITION AND METHODS OF USE Diadexus, Inc. (US) 2006-03-15 EP disclosed
EP-1633784-A2 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE Diadexus, Inc. (US) 2006-03-15 EP disclosed
WO-2006010077-A2 PRODRUGS OF LONIDAMINE AND LONIDAMINE ANALOGS THRESHOLD PHARMACEUTICALS, INC. (US) 2006-01-26 WO disclosed
WO-2005095454-A1 LNG105 ANTIBODY COMPOSITION AND METHODS OF USE, AND USE OF LNG105 TO ASSESS LUNG CANCER RISK DIADEXUS, INC. (US) 2005-10-13 WO disclosed
US-20050124012-A1 Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk DIAZYME LABORATORIES, INC. 2005-06-09 US disclosed
WO-2005046573-A2 Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS, INC. (US) 2005-05-26 WO disclosed
WO-2005021709-A2 CLN101 ANTIBODIES DIADEXUS, INC. (US) 2005-03-10 WO disclosed
WO-2004104173-A2 Ovr115 ANTIBODY COMPOSITION AND METHODS OF USE DIADEXUS, INC. (US) 2004-12-02 WO disclosed
WO-2004101756-A2 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS, INC. (US) 2004-11-25 WO disclosed